Matthew Campbell

Dr Matthew Campbell graduated from University College Dublin (UCD) in 2006 with a PhD in Biochemistry followed by Post-doctoral research in Trinity College Dublin (TCD) in Human Molecular Genetics (2006-2012). He has published extensively on the use of RNA interference (RNAi) to modulate levels of distinct tight junction proteins at the blood-brain barrier/inner blood-retina barrier (BBB/iBRB) in vivo. Additionally, he has published numerous articles focused on understanding the molecular pathology of diseases such as age-related macular degeneration (AMD), Alzheimer's disease, Schizophrenia, traumatic brain injury (TBI) and chronic traumatic encephalopathy (CTE).

Matthew's laboratory focuses primarily on the molecular biology and physiology of the vasculature associated with neural tissues, using genetic and molecular biology-based approaches to explore the interplay between neural tissues and systemic circulation. One major research strand is centred on the tight junctions located between microvascular endothelial cells of the blood-brain and inner blood-retina barriers (BBB/iBRB) and how these barriers function in health and disease. The aim is to develop technologies to address an unmet clinical need for a range of neural conditions that currently have limited forms of therapeutic intervention and these include Alzheimer Disease, Multiple Sclerosis, Glioblastoma multiforme (GBM), traumatic brain injury (TBI), chronic traumatic encephalopathy.

In addition to translational interests, the lab is also heavily focused on elucidating the underlying mechanisms of the diseases studied, and this has led to novel findings associated with the molecular pathology of age-related macular degeneration (AMD) and schizophrenia. Identification of novel therapeutic targets has the potential to rapidly translate to new medicines.